TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04102371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-lyte
Description: PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
Study: NCT02135341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
Study: NCT03398837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg
Description: Subjects will receive lenabasum 5 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg
Description: Subjects will receive lenabasum 20 mg twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects will receive placebo twice daily.
Study: NCT04402320

Intervention type: DRUG
Intervention: Midazolam
Description: reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use

Intervention type: DRUG
Intervention: Midazolam
Description: reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use

Intervention type: DRUG
Intervention: Midazolam
Description: reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use

Intervention type: DEVICE
Intervention: ventilator
Description: reconnected to mechanical ventilation before extubation for one hour with sedation

Intervention type: DEVICE
Intervention: ventilator
Description: reconnected to mechanical ventilation before extubation for one hour with sedation

Intervention type: DEVICE
Intervention: ventilator
Description: reconnected to mechanical ventilation before extubation for one hour with sedation
Study: NCT02031471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Fixed dose of 162 mg subcutaneously weekly
Study: NCT02857647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An information video
Description: Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
Study: NCT03631368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
Study: NCT02787317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is used in patients undergoing percutaneous coronary intervention.
Study: NCT03427476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging.
Study: NCT00686439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: subcutaneous injection 40mg on alternate weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: subcutaneous injection 40mg every other week
Study: NCT01343069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implementation surgical checklist
Description: a checklist according to the suggestions raised by the WHO is implementated
Study: NCT02385201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza
Description: Spinal Cord Stimulation
Study: NCT00616044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous spinal anesthesia
Description: bupivacaina isobaric 0.5%, 5 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinocath a catheter for continuous spinal anesthesia
Description: Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinocath a catheter for continuous spinal anesthesia
Description: Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined spinal epidural anesthesia
Description: CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
Study: NCT02168140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study: NCT00556491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
Study: NCT03618329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: exercise, nutrition and anxiety reduction in the preoperative period
Study: NCT03138824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPIES assisted TURBT
Description: SPIES assisted TURBT of NMIBC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WLI assisted TURBT
Description: White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
Study: NCT01473550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to TELUS Health Space and Smart Phone
Description: Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to TELUS Health Space and Smart Phone
Description: Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
Study: NCT03746002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone 60 minutes prior to furosemide
Description: All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone concurrently with furosemide
Description: All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
Study: NCT01709994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100 mg/day of aspirin
Study: NCT03764735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose - SkQ1
Description: SkQ1 Low dose ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose - SkQ1
Description: SkQ1 High Dose ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SkQ1 (Vehicle)
Description: Vehicle for SkQ1 ophthalmic solution
Study: NCT02216799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine Insulin
Description: 80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine Insulin
Description: 80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: 80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: 80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
Study: NCT04060511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10342
Description: HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
Study: NCT04177641

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study: NCT06331377

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT03910075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACQUIRE - High Dosage
Description: Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACQUIRE - Moderate Dosage
Description: Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual & Customary Treatment (U&CT)
Description: Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
Study: NCT04533945

Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre
Description: The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
Study: NCT02716441

Intervention type: DEVICE
Intervention: Radio-opaque Tissue Markers
Description: All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
Study: NCT03190421

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Expanded Urinary Culture
Description: involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urine Culture (SUC)
Description: involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
Study: NCT04500145

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Description: 60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time

Intervention type: RADIATION
Group type: OTHER
Intervention: routine IMRT
Description: patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
Study: NCT02398331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardised information and education on sexuality in women with spinal cord injury
Description: Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury
Study: NCT02036346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Ηydration Solution
Description: Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advise on calculated oral fluid requirements
Study: NCT02296619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A sham band-aid will be applied to the abdomen of subjects
Study: NCT04483063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate skin cleanser
Description: 2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate skin cleanser
Description: 2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
Study: NCT02036346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No nutritional advice will be given
Study: NCT03943277

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention observational study

Intervention type: OTHER
Intervention: No intervention, observational study
Description: No intervention observational study
Study: NCT02804620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes
Description: The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
Study: NCT01395134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring
Description: Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
Study: NCT01872884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevorane Remifentanil
Description: Sevorane Remifentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil
Study: NCT03167905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultiva
Description: Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study: NCT02362581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylaxis treatment, on demand treatment
Study: NCT02672826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose tissue surgery
Description: Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
Study: NCT03329508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2B001 0.6/0.75 mg
Description: Fixed low dose extended release combination capsule of pramipexole and rasagiline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline 0.75 mg
Description: Rasagiline 0.75 mg oral extended release capsule, component

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.6 mg
Description: Pramipexole 0.6 mg oral extended release capsule, component

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Pramipexole ER
Description: Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet